NCT07932002 Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
| NCT ID | NCT07932002 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | IMMUNOe Research Centers |
| Condition | Post SARS-CoV2 (COVID-19) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-05 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 30 participants in total. It began in 2025-11-05 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Assessment of RUCONEST (C1 Esterase Inhibitor \[Recombinant\]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens
Eligibility Criteria
Inclusion Criteria: * Age 18 and older, male or female * Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations. * Patients who were involved in the previous study with defined post-COVID neurologic symptoms. * New patients who have been diagnosed with post-COVID neurologic symptoms. Exclusion Criteria: * Receiving any form of C1-INH therapy, either acute or prophylactic treatment * History or suspicion of allergy to rabbits * Neurological conditions related to injury * Neuropathy related to diabetes * Abnormal kidney or liver enzymes * History of thrombotic stroke * Participants who are pregnant or lactating * Largely incapacitated or bed-ridden * Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued within 30 days of study entry from any other clinical study involving and investigational product.
Frequently Asked Questions
Who can join the NCT07932002 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Post SARS-CoV2 (COVID-19). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07932002 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07932002 currently recruiting?
Yes, NCT07932002 is actively recruiting participants. Visit ClinicalTrials.gov or contact IMMUNOe Research Centers to inquire about joining.
Where is the NCT07932002 trial being conducted?
This trial is being conducted at Centennial, United States.
Who is sponsoring the NCT07932002 clinical trial?
NCT07932002 is sponsored by IMMUNOe Research Centers. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.